Sustained Viral Response (SVR)
/ Rapid Virologic Response (RVR)
/ Early Viral Response (EVR)
/ End of Treatment Response (EOT)

Genotype 1 Chronic Hepatitis C Patients with Low Viral Load Can Achieve Sustained Response with 24 Weeks of Pegylated Interferon plus Ribavirin
11/17/09

Individually Tailored Duration of Hepatitis C Treatment Does Not Improve Virological Response
10/30/09

Interferon-based Therapy for Hepatitis C Improves Fibrosis Even in Individuals without Virological Response
4/21/09

Sustained Response to Interferon-based Therapy Reduces Risk of Diabetes in Hepatitis C Patients
4/21/09

A Small Proportion of Hepatitis C Patients Develop Liver Cancer despite Sustained Response to Interferon-based Therapy
4/13/09

Hepatitis C Virus May Persists at Low Levels after Sustained Response to Treatment; Liver Cancer May Develop Years Later
2/06/2009

Extended Pegylated Interferon plus Ribavirin Therapy Improves Sustained Response Rate in Slow Responder Genotype 1b Hepatitis C Patients
2/03/2009

Adherence to Pegylated Interferon/ribavirin Therapy for Hepatitis C and Early Treatment Response
1/30/2009

Sustained Virological Response Indicates Long-term HCV Eradication in People Successfully Treated for Chronic Hepatitis C
10/14/08

Higher Doses of Pegylated Interferon and Ribavirin May Increase Sustained Response Rates in Hard-to-Treat Patients with Chronic Hepatitis C
10/10/08

Sustained Virological Response to Pegylated Interferon plus Ribavirin for Chronic Hepatitis C Does Not Always Prevent Hepatocellular Carcinoma
10/10/08

Genetic Variation Linked to Sustained Response to Pegylated Interferon plus Ribavirin in HALT-C Trial
9/09/2008

Rapid Viral Response and Sustained Treatment Outcome: A Comparison between 2 HCV RNA Assays
8/05/2008

Eight Weeks of Pegylated Interferon plus Ribavirin for Genotype 2 Chronic HCV Patients with Rapid Virological Response (RVR)
8/05/2008

74 Percent of Genotype 1 HCV Patients in Experimental HCV PI Boceprevir Phase II Study Achieve Sustained Virologic Response (SVR) at 48 Weeks
8/05/2008

Telaprevir plus Pegylated Interferon and Ribavirin Produces Rapid Response and Is Well Tolerated in 28-day Study
7/22/08

Adequate Ribavirin Exposure after the First Dose Predicts Sustained Virological Response to Hepatitis C Treatment in Genotype 1 Patients
7/08/08

HCV Genotype 1 Patients with High Viral Load Do Better with 48 vs 24 Weeks of Treatment, despite Rapid Virological Response
7/04/08

European Commission Approves Shorter 16-week Course of Pegasys plus Ribavirin for Rapid Responders with HCV Genotypes 2 or 3 and Low Viral Load
7/04/08

Sustained Response to Interferon-based Therapy Reduces the Likelihood of Type 2 Diabetes
- 6/24/08

Sustained Response to Interferon-based Therapy Reduces the Likelihood of Type 2 Diabetes
- 6/24/08

Sustained Virological Response to Pegylated Interferon Alfa-2b (PegIntron) with or without Ribavirin Predicts Continued Response through 5 Years
5/30/08

Very Early Response to Interferon-based Therapy for Hepatitis C Is Apparent within the First 24 Hours
5/30/08

Duration of Pegylated Interferon plus Ribavirin May Be Tailored Based on Early Response
1/04/08